Sign In
Buy PODD
$143.30
+0.87 (+0.611%)
At Close: Jun 03, 2026
Insulet Corporation (PODD) CEO Shacey Petrovic on Q1 2021 Results - Earnings Call Transcript
01:43am, Friday, 07'th May 2021
Insulet Corporation (PODD) CEO Shacey Petrovic on Q1 2021 Results - Earnings Call Transcript
Insulet (PODD) Reports Break-Even Earnings for Q1
06:01pm, Thursday, 06'th May 2021
Insulet (PODD) delivered earnings and revenue surprises of -100.00% and 2.96%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Insulet to Present at BofA Securities 2021 Virtual Healthcare Conference
06:00am, Tuesday, 04'th May 2021
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management
Insulet 2020 Sustainability Report Conveys Strategy to Deliver Growth with Purpose
06:00am, Monday, 03'rd May 2021
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced
Insulet to Announce First Quarter 2021 Financial Results on May 6, 2021
06:00am, Monday, 05'th Apr 2021
ACTON, Mass.--(BUSINESS WIRE)--Q1'21 Earnings Release Schedule
Insulet Stock Rises as It Joins the Automated Insulin Device Competition
07:14pm, Monday, 22'nd Mar 2021
The company's popular insulin pumps demonstrated the ability to automatically regulate glucose levels for their diabetic users.
PODD Stock Price: $280 Target By Canaccord
06:18am, Monday, 22'nd Mar 2021
The stock price of Insulet Corporation (NASDAQ: PODD) has received a price target of $280 by Canaccord Genuity. These are the details.
Insulet's Omnipod® 5 Automated Insulin Delivery System Improves Clinical Outcomes in Type 1 Diabetes
11:45am, Saturday, 20'th Mar 2021
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced
4 Stocks in Focus as Diabetes Sector Grows Amid Pandemic
09:39am, Friday, 19'th Mar 2021
Here are a few diabetes-centric MedTech stocks, ABT, NVO, MDT, PODD and TNDM, which investors can focus on to reap profits in the new normal.
Insulet to Host an Investor Webcast to Discuss Omnipod® 5 Pivotal Data
04:01pm, Tuesday, 16'th Mar 2021
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced
Insulet (PODD) Q4 Earnings Fall Shy of Estimates, Revenues Beat
10:38am, Wednesday, 24'th Feb 2021
Insulet's (PODD) Q4 revenues were significantly boosted by the robust adoption of Omnipod DASH and a growing customer base.
Insulet Corporation (PODD) CEO Shacey Petrovic on Q4 2020 Results - Earnings Call Transcript
11:54pm, Tuesday, 23'rd Feb 2021
Insulet Corporation (PODD) CEO Shacey Petrovic on Q4 2020 Results - Earnings Call Transcript
Recap: Insulet Q4 Earnings
04:45pm, Tuesday, 23'rd Feb 2021
Shares of Insulet (NASDAQ:PODD) moved lower in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were down 425.00% year over year to ($0.26), which misse
Top Healthcare Stocks for February 2021
02:15pm, Tuesday, 19'th Jan 2021
These are the healthcare stocks with the best value, fastest growth, and most momentum for February 2021.
Insulet (PODD) Omnipod DASH Reaches Canada, Global Hold Widens
10:32am, Tuesday, 19'th Jan 2021
Insulet's (PODD) Omnipod DASH system provides 72 hours of continuous insulin therapy, simplifying lives with no more daily injection.
